the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma (clinicaltrials.gov) - Nov 3, 2022 - P1 | N=86 | Recruiting | Sponsor: University Hospital Tuebingen | Trial completion date: Sep 2022 ➔ Aug 2023 | Trial primary completion date: Mar 2022 ➔ Mar 2023
Trial completion date • Trial primary completion date • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • IL2 • IL6
|